Home / News / CMS advises EPIRUS Biopharmaceuticals, Inc. on the...

CMS advises EPIRUS Biopharmaceuticals, Inc. on the acquisition of Bioceros Holding B.V.

24/09/2015

CMS has advised EPIRUS Biopharmaceuticals, Inc. on the acquisition of Bioceros Holding B.V. EPIRUS Biopharmaceuticals, Inc. is a NASDAQ listed biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). This acquisition enables EPIRUS to expand its biosimilar pipeline.

Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines.

The CMS team that assisted EPIRUS comprised Reinout Slot, Clair Wermers, Tjeerd Hoekstra, Katja van Kranenburg-Hanspians, Paulus van den Bos, Niels Koene, Rogier de Vrey, Ellen Gielen, Dena Mokhberolsafa, Kirsten van Vliet and Erik Vorst.

Related people

Portrait of Reinout Slot
Reinout Slot
Partner
Amsterdam
Portrait of Clair Wermers
Clair Wermers
Partner
Amsterdam
Portrait of Tjeerd Hoekstra
Tjeerd Hoekstra
Advocaat
Amsterdam
Portrait of Katja Kranenburg - Hanspians
Katja van Kranenburg - Hanspians
Partner
Amsterdam
Portrait of Niels Koene
Niels Koene
Advocaat
Amsterdam
Portrait of Rogier Vrey
Rogier de Vrey
Partner
Amsterdam
Portrait of Ellen Gielen
Ellen Gielen
Partner
Utrecht
Portrait of Dena Mokhberolsafa
Dena Mokhberolsafa
Advocaat
Amsterdam
Portrait of Erik Vorst
Erik Vorst
Partner
Amsterdam
Paulus van den Bos
Kirsten van Vliet
Show more Show less